Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Karolinska Development AB ( (SE:KDEV) ) has issued an update.
Karolinska Development AB has divested its remaining shares in OssDsign, generating a capital injection of approximately SEK 34.5 million. This decision reflects the company’s strategy to strengthen its financial position and prioritize investments with greater potential for value creation and higher returns. The divestment marks the end of Karolinska Development’s direct ownership in OssDsign, although it retains an indirect stake through the KCIF Co-Investment Fund.
More about Karolinska Development AB
Karolinska Development AB is a Nordic life sciences investment company focusing on breakthrough medical innovations in the Nordic region. The company invests in the growth of companies that develop commercial products aimed at improving patients’ lives while ensuring attractive returns for shareholders. It has a portfolio of eleven companies targeting innovative treatments for serious diseases and leverages world-class medical innovations from the Karolinska Institutet and other leading research institutes.
Average Trading Volume: 210,243
Current Market Cap: SEK278.5M
Learn more about KDEV stock on TipRanks’ Stock Analysis page.